Literature DB >> 35949578

Author's reply.

Wataru Takahashi1, Takehiro Morita1, Kiu Tanaka1, Shougo Ide1, Kouki Fujimori1.   

Abstract

Entities:  

Keywords:  Antiphospholipid syndrome; Limb-threatening ischemia; No consensus treatment guideline

Year:  2022        PMID： 35949578      PMCID： PMC9352405          DOI： 10.1016/j.jccase.2022.03.004

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN： 1878-5409


× No keyword cloud information.
  5 in total

1.  Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies.

Authors:  G Ruiz-Irastorza; M J Cuadrado; I Ruiz-Arruza; R Brey; M Crowther; R Derksen; D Erkan; S Krilis; S Machin; V Pengo; S Pierangeli; M Tektonidou; M Khamashta
Journal:  Lupus       Date:  2011-02       Impact factor: 2.911

2.  Validation of CHA₂DS₂-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation: an analysis of the J-RHYTHM Registry.

Authors:  Ken Okumura; Hiroshi Inoue; Hirotsugu Atarashi; Takeshi Yamashita; Hirofumi Tomita; Hideki Origasa
Journal:  Circ J       Date:  2014-04-22       Impact factor: 2.993

3.  Rivaroxaban in Peripheral Artery Disease after Revascularization.

Authors:  Marc P Bonaca; Rupert M Bauersachs; Sonia S Anand; E Sebastian Debus; Mark R Nehler; Manesh R Patel; Fabrizio Fanelli; Warren H Capell; Lihong Diao; Nicole Jaeger; Connie N Hess; Akos F Pap; John M Kittelson; Ivan Gudz; Lajos Mátyás; Dainis K Krievins; Rafael Diaz; Marianne Brodmann; Eva Muehlhofer; Lloyd P Haskell; Scott D Berkowitz; William R Hiatt
Journal:  N Engl J Med       Date:  2020-03-28       Impact factor: 91.245

4.  Management of peripheral arterial interventions with mono or dual antiplatelet therapy--the MIRROR study: a randomised and double-blinded clinical trial.

Authors:  Gunnar Tepe; Rüdiger Bantleon; Klaus Brechtel; Jörg Schmehl; Thomas Zeller; Claus D Claussen; Frederik F Strobl
Journal:  Eur Radiol       Date:  2012-05-10       Impact factor: 5.315

5.  Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial.

Authors:  Josep Ordi-Ros; Luis Sáez-Comet; Mercedes Pérez-Conesa; Xavier Vidal; Antoni Riera-Mestre; Antoni Castro-Salomó; Jordi Cuquet-Pedragosa; Vera Ortiz-Santamaria; Montserrat Mauri-Plana; Cristina Solé; Josefina Cortés-Hernández
Journal:  Ann Intern Med       Date:  2019-10-15       Impact factor: 25.391
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.